Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer
Status:
Completed
Trial end date:
2017-08-04
Target enrollment:
Participant gender:
Summary
Panacea is a phase Ib/II trial evaluating the efficacy of MK-3475 and trastuzumab in patients
with trastuzumab-resistant, HER2- positive metastatic breast cancers